Drug Injury Claims Cause Actos Sales to Plunge
Reports surfaced early today that profits for Japan-based Takeda Pharmaceutical Co. have substantially declined.
Reports surfaced early today that profits for Japan-based Takeda Pharmaceutical Co. have substantially declined. One factor that several news sources, including Bloomberg Businessweek, have attributed to the company’s losses is the controversy surrounding its top-selling drug, Actos. Calls for the FDA to release cautionary warnings for the diabetes medication began to emerge after it was linked to an increased risk of bladder cancer. Takeda projects that its net income will plunge by over 30 percent over the course of the next four months.
In a Feb. 1 settlement, German automaker Volkswagen agreed to fully compensate American consumers who purchased 3.0-liter diesel engine vehicles equipped with the company’s rigged “clean diesel” emissions testing devices. The company [...]February 3, 2017 By: Seeger Weiss read more
On January 24, the Supreme Court of New Jersey unanimously restored a $25 million verdict for a Seeger Weiss LLP client who sued the drug manufacturer Hoffmann-La Roche after suffering side effects [...]January 30, 2017 By: Seeger Weiss read more